文献速递泌尿生殖与妇科肿瘤放疗姑息放疗与转移瘤

立体定向体部放疗在寡进展前列腺癌中的作用:RADIANT II期试验的部位特异性分析

The role of stereotactic body radiotherapy in oligoprogressive prostate cancer: A site-specific analysis of the prospective, phase II RADIANT trial.
PubMed 文献 · Radiother Oncol · 2025-07-08

RADIANT是一项单臂II期篮式试验,纳入接受系统治疗≥3个月且≤5个部位影像学寡进展的转移性前列腺癌患者,按部位预设分析。

要点

  • 寡进展前列腺癌患者接受SBRT后1年局部控制率为84.0%。
  • 1年时55.1%患者维持原系统治疗线,2级毒性累积发生率25.0%,无3级以上毒性。
  • SBRT后健康相关生活质量维持,无损害。

核心结论

  • 在寡进展前列腺癌患者中,SBRT是有效且安全的干预措施,包括具有侵袭性临床病理特征的患者。
  • 需要更大规模的随机试验来验证这些发现。

研究设计与样本

  • RADIANT(NCT04122469)是一项单臂II期篮式试验。
  • 纳入接受任何系统治疗≥3个月、影像学证据显示≤5个部位寡进展的转移性前列腺癌患者。
  • 按疾病部位分析为预设分析。
  • 患者接受1-5次SBRT照射所有进展部位,并维持当前系统治疗。
  • 主要终点为系统治疗改变的累积发生率。

主要发现

  • 中位随访14.1个月(范围4.8-51.9个月)。
  • 1年时55.1%患者维持原系统治疗线,局部控制率为84.0%。
  • 1年2级毒性累积发生率为25.0%,无3级以上毒性。
  • 健康相关生活质量维持,SBRT后无损害。

关键数值与推荐

  • 寡进展定义为影像学证据显示≤5个进展部位。
  • SBRT剂量分割为1-5次。
  • 主要终点为系统治疗改变的累积发生率。

临床怎么用

  • 对于接受系统治疗≥3个月后出现≤5个部位寡进展的转移性前列腺癌患者,可考虑对进展部位行1-5次SBRT并维持原系统治疗。
  • SBRT后需关注2级毒性(1年累积发生率25.0%)及健康相关生活质量。

局限性

  • 需要更大规模的随机试验验证 findings。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND PURPOSE: Changing to next-line systemic therapy is the standard-of-care for patients with progressive metastatic castrate-resistant prostate cancer. However, to preserve systemic therapy options and minimize toxicity, stereotactic body radiation therapy (SBRT) is being increasingly considered for patients with limited disease progression ('oligoprogression'). Herein, we report clinical, toxicity and quality of life (QOL) outcomes for an oligoprogressive prostate cancer cohort from a prospective trial. MATERIALS AND METHODS: RADIANT (NCT04122469) was a single-arm, phase-II basket trial which included patients with metastatic prostate cancer on any systemic therapy ≥ 3 months, with radiographic evidence of oligoprogression in ≤ 5 sites. Analysis by disease site was planned a priori. Patients received SBRT in 1-5 fractions to all progressive sites and were maintained on their current systemic therapy. The primary endpoint was cumulative incidence of change in systemic therapy. Key secondary endpoints included local control, toxicity and health-related (HR) QOL. RESULTS: Thirty-two patients were analyzed; median age was 74.0 years, median PSA 6.7 µg/L, 25% with visceral metastases and a median of 2 prior systemic therapy lines. Median follow-up was 14.1 months (range 4.8-51.9 months). At 1-year, 55.1% of patients remained on the same systemic line and local control was 84.0%. The cumulative incidence of grade 2 toxicity was 25.0% at 1 year, with no grade 3+ toxicities. HRQOL was maintained, with no detriment following SBRT delivery. CONCLUSION: Among patients with oligoprogressive prostate cancer, SBRT is an effective and safe intervention, including in patients with aggressive clinicopathologic features. Larger, randomized trials are needed to validate these findings.

来源:Radiother Oncol,查看原文。版权归原作者所有。

引用

  1. Ruicci KM, Barry A, Ye XY, et al. The role of stereotactic body radiotherapy in oligoprogressive prostate cancer: A site-specific analysis of the prospective, phase II RADIANT trial. Radiother Oncol. 2025. PMID: 40639764. doi:10.1016/j.radonc.2025.111041

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。